Drivers and mechanisms of cognitive decline in chronic kidney disease
- PMID: 40281076
- PMCID: PMC12279462
- DOI: 10.1038/s41581-025-00963-0
Drivers and mechanisms of cognitive decline in chronic kidney disease
Abstract
Cognitive impairment is highly prevalent among individuals with chronic kidney disease (CKD). Despite its high prevalence, the contributing factors and mechanisms underlying brain-kidney dysfunction in CKD remain poorly understood. However, advances in neuroscience, including novel imaging techniques and cognitive assessment methods, have begun to clarify this complex relationship. Several factors contribute directly to cognitive decline in people with CKD, including accumulation of uraemic toxins, microvascular damage, malnutrition, chronic inflammation and disruptions in key neuroprotective pathways, such as those involving Klotho and the glymphatic system. These factors are also linked to the accelerated ageing observed in people with CKD, a key contributor to cognitive decline. However, most studies on cognition in people with CKD have been cross-sectional and associative, offering limited insight into causation. Research advances, such as studies on the effect of uraemic toxins on the blood-brain barrier and the role of the endothelial glycocalyx in vascular damage, offer promising new directions. Emerging data from longitudinal cohort studies are also enhancing our understanding of these processes, with potential implications for both the treatment of CKD-related cognitive decline and the broader issue of cognitive dysfunction in ageing populations. Here, we examine key mechanisms linking CKD to cognitive decline and consider potential therapeutic interventions.
© 2025. Springer Nature Limited.
Conflict of interest statement
Competing interests: A.O. has received grants from Sanofi, and consultancy or speaker fees or travel support from Adviccene, Alexion, Astellas, Astrazeneca, Amicus, Amgen, Bioporto, Boehringer Ingelheim, Esteve, Fresenius Medical Care, GSK, Bayer, Sanofi-Genzyme, Sobi, Menarini, Mundipharma, Kyowa Kirin, Lilly, Freeline, Idorsia, Chiesi, Otsuka, Novo-Nordisk, Sysmex and Vifor Fresenius Medical Care Renal Pharma and Spafarma; is the Director of the Catedra UAM-Astrazeneca of chronic kidney disease and electrolytes; and owns Telara Farma stock. C.F.M.F. received research grants from Baxter, Fresenius and Sandoz; and is on the Advisory board of Pharvaris. C.A.W. reports honoraria from Kyowa Kirin and Medice; and scientific collaboration with Bayer AG. M.D.O. is on the scientific advisory board of AstraZeneca. R.I.M. is currently employed as Senior Director Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. Z.A.M. reports grants from Amgen, Baxter, Fresenius Medical Care, GlaxoSmithKline, Merck Sharp and Dohme-Chibret, Genzyme/Sanofi, Lilly, Otsuka and Boehringer Ingelheim; Government support for CKD REIN PROJECT AND EXPERIMENTAL PROJECTS; and payment or honoraria for lectures and presentations to charities from AstraZeneca, GSK and Boehringer Ingelheim. R.J.U. is currently employed as a Chief Scientist by AstraZeneca Biopharmaceuticals R&D, Translational Science and Experimental Medicine (TSEM), and Early Cardiovascular, Renal and Metabolism (eCVRM), Cambridge, UK. M.N. is a paid consultant for CNS2 for unrelated work. The other authors declare no competing interests.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
